Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates
Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +26.19% and -5.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?